Hit Enrollment Targets Without Adding Sites
Sponsors using TrialVyx identify more eligible patients within their existing site network — reducing reliance on site expansion and improving screen-to-enroll ratios across every phase.
Why Trials Fall Behind Schedule
More than 80% of clinical trials fail to meet original enrollment timelines. The root cause is rarely scientific — it's operational: sites cannot identify eligible patients fast enough.
Poor Patient Visibility
Sites often rely on manual chart review or ad-hoc referrals. Eligible patients are in the EHR but not identified until months into the trial — or never.
High Screen Failure Rates
Industry median screen failure is 40–60% across therapeutic areas. Each failure costs $2,000–$8,000 and burns coordinator capacity that could be spent on enrolled patients.
Site Expansion Costs
Adding sites to fix enrollment shortfalls adds CRO overhead, site activation delays, and new variability. The average cost of activating a new site is $40,000–$120,000.
Sponsor-Side Benefits
Continuous EHR Scanning
TrialVyx continuously monitors de-identified EHR data at your partner sites, surfacing newly eligible patients as their clinical status changes — including patients who become eligible partway through the trial.
Pre-Screened Referral Packets
Sites receive structured referrals with match confidence scores and key eligibility signals. Coordinators start conversations with pre-screened candidates — reducing screen failure from the first contact.
Sponsor Dashboard Visibility
Sponsors have a real-time dashboard showing referral pipeline, screen failure rates, and enrollment trajectory. Identify which sites are underperforming and where patient pools are thinnest — without waiting for monthly CRO reports.
Protocol Amendment Synchronization
When inclusion/exclusion criteria change, the matching engine re-scores all existing phenotype profiles immediately. Sponsors see the projected impact on eligible patient volume before the amendment is submitted.
The ROI of Faster Enrollment
Every day of enrollment delay has a measurable cost. Shortening the recruitment window by even 30% compresses the path to first patient data, study lock, and NDA filing.
Read the Case Study"We moved from 22 months projected enrollment to 11 months actual. The phenotype identification found patients we'd have completely missed with manual chart review."
How Sponsor Deployment Works
Pilot Scoping
We start with your active protocol and identify 2–5 sites for pilot deployment. Scoping call covers EHR compatibility, protocol complexity, and enrollment history.
Integration & Activation
Site EHR connections are established with de-identification validation. Protocol criteria are mapped to computable phenotype dimensions. Average time-to-first-referral: 3 weeks from activation.
Active Recruitment
Referrals flow to your site coordinators daily. The sponsor dashboard shows pipeline, match confidence distribution, and referral-to-consent conversion rate in real time.
Review & Scale
At 90 days, you review pilot metrics vs. pre-deployment baseline. Sponsors typically expand to full site network after pilot confirmation.
Start Your Sponsor Pilot
TrialVyx pilots launch within 3 weeks of scoping. 90-day evaluation period. Full EHR phenotype deployment on your active protocol — measured against your pre-deployment baseline from day one.
Request Pilot Access